It is therefore postulated that enhancement of Sirt1 expression or activity in EAT might be considered as a therapeutic strategy to impend development and progression of CAD through suppressing of the p53-dependent apoptosis in atherosclerotic area. The gene discussed is TP53; the disease is coronary artery disorder.